Item 8.01 Other Events.

On June 22, 2020, Principia Biopharma Inc. (the "Company") issued a press release announcing that its partner Genzyme Corporation ("Sanofi") had enrolled the first patient in Sanofi's Phase 3 clinical trial of SAR442168, formerly known as PRN2246, in patients with relapsing multiple sclerosis. Pursuant to the License Agreement by and between the Company and Sanofi dated as of November 8, 2017, and as amended on May 24, 2018, upon dosing of the first patient, Principia will be entitled to a $50.0 million milestone payment from Sanofi.

A copy of this press release is attached as Exhibit 99.1 hereto.

Item 9.01Financial Statements and Exhibits.





Exhibit
Number                                    Description
 99.1
            Press Release issued by Principia Biopharma Inc. dated June 22, 2020
  104     Cover Page Interactive Data File (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses